Precision Cancer Therapy for Lymphoma & Colorectal Cancer
Fighting Lymphoma and Colorectal Cancer Through In-Depth Research
Tags: SingHealth Duke-NUS, Singapore, Healthcare & Lifesciences
The National Cancer Centre Singapore is leading two major research initiatives, SYMPHONY 2.0 and Colo-SCRIPT, backed by a $50 million grant from the National Medical Research Council. SYMPHONY 2.0 focuses on developing an AI platform for personalized multi-drug therapies for lymphoma and enhancing access to CAR-T cell therapy, while Colo-SCRIPT aims to categorize colorectal cancer (CRC) into subtypes to personalize treatment approaches. Both programs involve collaboration with institutions such as A*STAR and the Cancer Science Institute of Singapore. Applications include identifying precise drug combinations for blood cancer patients and establishing new CRC detection and treatment protocols. The insights from these projects promise advancements in cancer care through subtype-specific therapies.
IP Type or Form Factor: Platform
TRL: 4 - minimum viable product built in lab
Industry or Tech Area: Biotechnology; Healthcare Provider
